

# **Predictors of success of laparoscopic ovarian drilling in patients with Clomiphene Citrate resistant polycystic ovarian disease**

*Thesis*

*Submitted for partial fulfilment of master degree in  
Obstetric and gynaecology*

*By*

**Marian Samir Gendy khalil**

*M.B., B.CH  
Ain Shams university (2005)  
Resident of obstetric and gynaecology  
Imbaba hospital*

*Supervision of*

**Professor. Hassan Awwad Bayoumy**

*Professor of obstetric and gynaecology  
Faculty of medicine, Ain Shams University*

**Dr. Wessam Magdi Abuelghar**

*Lecturer of obstetric and gynaecology  
Faculty of medicine, Ain Shams University*

**Faculty of Medicine**

**Ain Shams university**

**2013**



## Acknowledgement

*First and before all, I thank **ALLAH**. I thank him for his great mercy, generous blesses, and for his continuous gifts.*

*I would like to express my sincere thanks and gratitude to **Professor Dr. Hassan Auwad Bayoumy**, Professor of obstetrics and gynaecology, Faculty of Medicine, Ain Shams University, who helped me a lot by continuous guidance and encouragement. He had the idea of this work and I owe her choosing me to do it.*


*I am greatly indebted to **Dr. Wessam Magdi Abuelghar**, Lecturer of obstetrics and gynaecology, Faculty of Medicine, Ain Shams University, who gave me valuable directions throughout the work. I was honoured that he accepted the supervision of this work.*

*Special thanks to Dr. Mohamed Ibrahim Ellaithy, lecturer of Obstetrics & Gynaecology, Ain-shams University for his valuable scientific advice and contributions, he critically reviewed the data analysis and thesis edition.*

*Many thanks for d. Nashwa El Khazragy professor of biochemistry of Oncology Diagnostic unit, Faculty of Medicine, Ain Shams University, for her great effort*

*Finally, my sincere thanks to **my parents** who supported me a lot throughout my life and never gave up from me and i would never be here without them.*

*A special thanks to **my Fiance'** who always support me and never give upset because of my anxiety. Thanks a lot my kind & wonderful partner.*



# *List of Contents*

<i>Title</i>	<i>Page</i>
Introduction.....	1
Aim of the Work.....	2
Therapeutic options of polycystic ovarian syndrome.....	3
Laparoscopic Ovarian Drilling.....	26
Factors affecting the outcome of laparoscopic ovarian drilling for polycystic ovarian syndrome in women with anovulatory infertility .....	49
Patient& Methods .....	65
Statistical .....	75
Results .....	78
Discussion .....	96
Summary .....	107
Conclusion .....	109
References .....	110
Appendices .....	-
<b>Arabic summary</b>	

## *List of abbreviation*

<b>AMH</b>	Anti-mullerian hormone
<b>Anti-A</b>	Anti-androgen.
<b>ARTs</b>	Artificial reproductive techniques
<b>ASRM</b>	American Society for Reproductive Medicine
<b>AUC</b>	Area under the curve
<b>BMI</b>	Body mass index
<b>CBC</b>	Complete blood picture
<b>CC</b>	Clomiphene citrate
<b>CCR-PCOD</b>	Clomiphene citrate resistance- Polycystic ovarian disease
<b>CI</b>	Confidence interval
<b>CVD</b>	Cardiovascular disease
<b>DM2</b>	Diabetes mellitus type 2
<b>E2</b>	Estradiol
<b>ELISA</b>	Enzyme linked Immunosorbent assay
<b>ESHRE</b>	European Society of Human Reproduction and Embryology
<b>FAI</b>	Free androgen index
<b>FDA</b>	
<b>FSH</b>	Follicle stimulating hormone
<b>GnRH</b>	Gonadotropin releasing hormone
<b>HCG</b>	Human chorionic gonadotrophin
<b>HOMA RI</b>	Homeostasis model assessment resistance index
<b>IUI</b>	Intra-uterine insemination
<b>IVF</b>	In-vitro fertilization

## *List of abbreviation (Cont...)*

<b>LH</b>	Luteinizing hormone
<b>LOD</b>	Laparoscopic ovarian drilling
<b>LOS</b>	Laparoscopic ovarian surgery
<b>MF</b>	Metformin
<b>NAC</b>	N-acetylcysteine
<b>OCP</b>	Oral contraceptive pills
<b>OHSS</b>	Ovarian hyperstimulation syndrome
<b>PCOS</b>	Polycystic ovarian syndrome
<b>POF</b>	Premature ovarian faliure
<b>PRL</b>	prolactin
<b>PSV</b>	Peak systolic velocity
<b>ROC</b>	Receiver operating characteristic curve
<b>SD</b>	Standard deviation
<b>SE</b>	standard error
<b>SHBG</b>	Sex hormone binding globulin
<b>VEGF</b>	Vascular endothelial growth factor
<b>WHO</b>	World health organization

## *List of Tables*

<i>Table No</i>	<i>Title</i>	<i>Page</i>
Table (1):	Descriptive statistics of the whole study population: Categorical data.....	78
Table (2):	Distribution of preoperative hormonal data....	79
Table (3):	Descriptive data of postoperative outcome of the whole study population: Categorical data	79
Table (4):	Mean and median time to ovulation.....	82
Table (5):	Mean and median time to menstruation.....	83
Table (6):	Relation of multiple clinical factors and ovulation outcome .....	84
Table (7):	Relation of multiple biochemical factors and ovulation outcome .....	87
Table (8):	Analysis of the ROC curve for prediction of successful ovulation using LH level.....	92
Table (9):	Analysis of the ROC curve for prediction of successful ovulation using FSH level.....	93
Table (10):	Analysis of the ROC curve for prediction of successful ovulation using androstenedione level	94
Table (11):	Mutiple logistic regression model for prediction of ovulation.....	95
Table (12):	Previous studies .....	105

## *List of Figures*

<b>Figure No.</b>	<b>Title</b>	<b>Page</b>
<b>Figure (1):</b>	Summary of a targeted approach to therapy in polycystic ovary syndrome (PCOS). ....	5
<b>Figure (2):</b>	CC administration using two distinct prediction models combined in a nomogram .....	10
<b>Figure (3):</b>	Laparoscopic Ovarian Drilling.....	26
<b>Figure (4):</b>	Diagram showing distribution of initial patient characteristics (polycystic ovaries [pco] on ultrasound, amenorrhea and obesity) in 240 mormogonadotropic anovulatory fertility patients (WHO <sub>2</sub> ) before treatment .....	39
<b>Figure (5):</b>	Patient flow chart .....	65
<b>Figure (6):</b>	Incidence of ovulation. ....	80
<b>Figure (7):</b>	Incidence of menstruation after surgery. ....	80
<b>Figure (8):</b>	Incidence of pregnancy after surgery. ....	81
<b>Figure (9):</b>	Kaplan-Meier curve for time to ovulation.....	82
<b>Figure (10):</b>	Kaplan-Meier curve for time to menstruation. ....	83
<b>Figure (11):</b>	Frequency distribution of age in the study population. ....	85
<b>Figure (12):</b>	Frequency distribution of weight in the study population. ....	85

## *List of Figures (Cont...)*

<b>Figure No.</b>	<b>Title</b>	<b>Page</b>
<b>Figure (13):</b>	Frequency distribution of BMI in the study population. ....	86
<b>Figure (14):</b>	Frequency distribution of duration of infertility in the study population. ....	86
<b>Figure (15):</b>	Frequency distribution of LH level in the study population. ....	88
<b>Figure (16):</b>	Frequency distribution of FSH level in the study population. ....	88
<b>Figure (17):</b>	Frequency distribution of testosterone level in the study population.....	89
<b>Figure (18):</b>	Frequency distribution of SHBG level in the study population. ....	89
<b>Figure (19):</b>	Frequency distribution of andros-tenedione level in the study population.....	90
<b>Figure (20):</b>	Receiver-Operating characteristic (ROC) curve derived from logistic regression model..	91
<b>Figure (21):</b>	Receiver-Operating characteristic (ROC) curve for prediction of incidence of ovulation using LH level. ....	92
<b>Figure (22):</b>	Receiver-Operating characteristic (ROC) curve for prediction of incidence of ovulation using FSH level. ....	93



## *List of Figures (Cont...)*

<i>Figure No.</i>	<i>Title</i>	<i>Page</i>
<b>Figure (23):</b>	Receiver-Operating characteristic (ROC) curve for prediction of incidence of ovulation using androstenedione level. ....	94

# Introduction

Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in women of reproductive age and the most common disorder of ovarian function in premenopausal women (*Slowey, 2001*).

The prevalence of PCOS cannot be determined with precision because it depends on the definition. A strict research-based definition that relies on endocrine characteristics is associated with a 3% prevalence of PCOS (*Guzick, 1990*) and for the clinical definition using chronic anovulation plus androgen excess, the prevalence of PCOS is 5-10% of premenopausal females (*Slowey, 2001*). PCOS represents most oligo-amenorrheic women (90%), most hirsute women (80%), and nearly one third of amenorrheic women (*Slowey, 2001*). The prevalence of PCOS is increased significantly with the irregularity of the menstrual cycle pattern, finding PCOS in 9% of the girls with regular menstrual cycles, 28% of the girls with irregular menstrual cycles, and 45% of oligo-amenorrheic girls (*Van Hoff et al., 2000*). The prevalence of PCOS among ovulatory women with infertility is higher than that in the normal population, suggesting that PCOS may, perhaps by virtue of an effect of Hyperandrogenaemia, contribute to the causes of sub-fertility in women with regular menses (*Kousta et al., 1999*).

## **Aim of the Work**

Is to evaluate the role of preoperative clinical, biochemical and pelvic ultrasound criteria as predictors of therapeutic success of LOD in patients with Clomiphene Citrate resistant polycystic ovarian disease.

# **Therapeutic options of polycystic ovarian syndrome**

Polycystic ovarian syndrome sometimes called hyperandrogenic chronic anovulation (*Balen, 1999*). the PCOS consensus workshop took place in Amsterdam, the Netherlands, in October 2010 , attempted to summarize current knowledge and to identify gaps in knowledge regarding various women's health aspects of PCOS agreed that PCOS was a primarily condition of ovarian dysfunction whose cardinal features were hyperandrogenism (either clinical or biochemical) and polycystic morphology on ultrasound. Criteria for the diagnosis of PCOS in adolescents differ from those used for older women of reproductive age. Groups at risk (e.g., obese, hirsute, irregular menses) should be identified, but physicians should be cautious of over diagnosing PCOS (**Carmina et al., 2010**). According to ASRM/ESHRE (American Society for Reproductive Medicine & European Society of Human Reproduction and Embryology) consensus meeting in Rotterdam, 2003, PCOS is characterized by two of the following three criteria were required in order to diagnose the condition after exclusion of the other causes of androgen excess. These three criteria were: (I) oligo-


and/anovulation, (ii) clinical and/or biochemical signs of hyperandrogenism; and (iii) polycystic ovary morphology on ultrasound scan, defined as the presence of 12 or more follicles in each ovary (with one ovary being sufficient for diagnosis) measuring 2-9 mm in diameter, and/or increased ovarian volume (>10 ml) (*Sharma et al., 2005*). In essence, *the Rotterdam 2003* expanded the *NIH 1990* definition creating two new phenotypes: a) ovulatory women with polycystic ovaries and hyperandrogenism, and b) Oligo-anovulatory women and polycystic ovaries, but without hyperandrogenism.

*Androgen Excess Society (2006)* defined PCOS to include all of the followings:

- (i) Hirsutism and/or Hyperandrogenaemia.
- (ii) Oligo- or anovulation and/or polycystic ovaries.
- (iii) Exclusion of androgen excess or related disorders.

Treatment options need to be tailored to the clinical presentation. Education on short-term and long-term sequelae of PCOS from a reliable independent source is important in allaying anxiety and minimising the impact of illness in chronic disease. As a prelude to treatment psychological features need to be acknowledged, discussed and counselling considered (*Huber et al., 1999*) to enable lifestyle change which is unlikely to be

successful without first addressing education and psychosocial issues (Figure 1).



**Figure (1):** Summary of a targeted approach to therapy in polycystic ovary syndrome (PCOS). (*Teede et al., 2008*).

Lifestyle change is first line treatment in an evidence-based approach in the management of the majority of PCOS women who are overweight (*Moran et al., 2009*). Furthermore, prevention of excess weight gain should be emphasized in all women with PCOS of both normal and increased body weight. As little as 5% to 10% weight loss has significant clinical benefits improving psychological outcomes (*Hamilton et al., 1993*),

reproductive features (menstrual cyclicity, ovulation and fertility and metabolic features (insulin resistance and risk factors for CVD and DM2). Evidence shows that lifestyle change with small achievable goals results in clinical benefits even when women remain in the overweight or obese range, (*Wahrenberg et al., 1999*). Standard dietary management of obesity and related co-morbidities (*Poehlman et al., 2000*) is a nutritionally adequate, low fat (approximately 30% of energy, saturated fat approximately 10%), moderate protein (approximately 15%) and high carbohydrate intake (approximately 55%), with increased fiber-rich wholegrain breads, cereals, fruits and vegetables and moderate regular exercise. A moderate energy reduction diet (500 to 1,000 kcal/day reduction) reduces body weight by 7% to 10% over a period of 6 to 12 months. Simple and practical tips that can be covered in minutes in medical consultation include targeting fruit juice, soft drinks, portion sizes and high-fat foods. Incorporating simple moderate physical activity including structured exercise (at least 30 min/day) and incidental exercise increases weight loss and improves clinical outcomes in PCOS, compared to diet alone (*Clinical Practice Guidelines for the Management of Overweight and Obesity in Adults ,Australia :2003*). Exercise alone also improves clinical outcomes. As in the